🇺🇸 Nevibolol in United States

35 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 35

Most-reported reactions

1. Atrial Fibrillation — 7 reports (20%)
2. Left Ventricular Hypertrophy — 5 reports (14.29%)
3. Mitral Valve Incompetence — 5 reports (14.29%)
4. Left Atrial Dilatation — 4 reports (11.43%)
5. Cholelithiasis — 3 reports (8.57%)
6. Confusional State — 3 reports (8.57%)
7. Affective Disorder — 2 reports (5.71%)
8. Cholecystitis — 2 reports (5.71%)
9. Drug-Induced Liver Injury — 2 reports (5.71%)
10. Fatigue — 2 reports (5.71%)

Source database →

Frequently asked questions

Is Nevibolol approved in United States?

Nevibolol does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Nevibolol in United States?

Spanish Society of Cardiology is the originator. The local marketing authorisation holder may differ — check the official source linked above.